title: Increased digitalis-like immunoreactive substances in neonatal plasma measured using fluorescence polarization immunoassay.
abstract: OBJECTIVE
  To better define the reported increased digitalis-like immunoreactive substances (DLIS) in neonatal plasma, we studied the relation among plasma DLIS level, blank intensity (BLK-I) value at FPIA measurement and plasma total bilirubin level.
  
  
  METHODS
  The DLIS levels were measured in 10 neonates with or without jaundice and 10 infants in good health, using fluorescence polarization immunoassay (FPIA) and microparticle enzyme immunoassay (MEIA). BLK-I value and plasma total bilirubin level were also measured simultaneously.
  
  
  RESULTS
  In neonates with jaundice, DLIS using FPIA, BLK-I and total bilirubin level were 0.58 +/-0.13 ng/mL, 2598 +/- 408, and 17.98 +/- 1.13 mg/dL, respectively, before phototherapy, and 0.33 +/-0.06 ng/mL, 1886 +/- 237, and 15.16 +/- 2.07 mg/dL after phototherapy. Corresponding values in neonates without jaundice were (DLIS: 0.34 +/-0.04 ng/mL; BLK-I: 1,764 +/- 278; total bilirubin: 10.37 +/- 4.54 mg/dL); in healthy infants (0.12 +/-0.06 ng/mL, 400.7 +/- 4.6 and 0.42 +/- 0.13 mg/dL, respectively) and in healthy volunteers (0.10 +/-0.07 ng/mL, 403.1 +/- 8.4, and 0.58 +/- 0.30 mg/dL, respectively). Using MEIA, DLIS was not detected in 10 neonates, 10 infants and 20 healthy volunteers.
  
  
  CONCLUSIONS
  A fluorescent compound related to bilirubin increased the BLK-I value in the measurement of neonatal plasma using FPIA. The fluorescence was not the result of endogenous digitalis-like factors.
authors.affiliation: Department of Pharmacy, Osaka Medical College Hospital, Osaka, Japan.
authors.forename: Y
authors.initials: Y
authors.lastname: Ijiri
authors.forename: T
authors.initials: T
authors.lastname: Hayahi
authors.forename: T
authors.initials: T
authors.lastname: Ogihara
authors.forename: K
authors.initials: K
authors.lastname: Ohi
authors.forename: K
authors.initials: K
authors.lastname: Suzuki
authors.forename: H
authors.initials: H
authors.lastname: Tamai
authors.forename: Y
authors.initials: Y
authors.lastname: Kitaura
authors.forename: H
authors.initials: H
authors.lastname: Takenaka
authors.forename: K
authors.initials: K
authors.lastname: Tanaka
mesh_terms: D001663:Bilirubin / Q000097:blood; D002298:Cardenolides; D002317:Cardiovascular Agents / Q000097:blood / Q000627:therapeutic use; D002675:Child, Preschool; D004077:Digoxin / Q000097:blood* / Q000627:therapeutic use; D005260:Female; D016231:Fluorescence Polarization Immunoassay / Q000379:methods; D006331:Heart Diseases / Q000097:blood / Q000188:drug therapy; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D007565:Jaundice / Q000097:blood / Q000628:therapy; D008297:Male; D010789:Phototherapy; D012016:Reference Values; D012503:Saponins / Q000097:blood*
chemical_list: D002298:Cardenolides; D002317:Cardiovascular Agents; D012503:Saponins; C034504:digoxin-like factors; D004077:Digoxin; D001663:Bilirubin